He also serves on the board of Aptinyx, a clinical-stage biopharmaceutical company focused on neurological disorders. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Mr. Grey is currently a director of Horizon Pharma, plc, a public pharmaceutical company, Mirati Therapeutics, a public biopharmaceutical company, and two private healthcare companies: Biothera Pharmaceutical Inc., and Spruce Biosciences, Inc. where he serves as Executive Chairman. Q: Hi Peter and Gang, I would appreciate your thoughts on Biomarin Pharmaceutical Inc. listed on NASDAQ either as a trade or a long-term hold. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . The business had revenue of $476.78 million during the quarter, compared to analyst estimates of $454.64 million. As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. He has also served as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. While we always look at total compensation first, our analysis … He received a B.Sc. Dr. Pyott is Lead Director and a member of the board of Avery Dennison Corporation, a public global labeling and packaging materials company, serves on the board of Alnylam Pharmaceuticals, Inc., a public biotechnology company; and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. ... Executive Vice President. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive … This is way … From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Implicit in this philosophy is the importance of sound … Traci McCarty - Vice President, Investor Relations. Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Average pay of disclosed executives at BioMarin Pharmaceutical. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $118.22. Between January and September 2009, he was President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$14b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. Mr. Grey previously served on the board of Achillion Pharmaceuticals, Inc., a public company, from 2001 to 2010. Notably, that's an increase of 18% over the year before. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. Apply on … Kristen Morris Executive Director, Global Medical Affairs at BioMarin Pharmaceutical Inc… Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. San Diego, CA -- -- 01/18/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc..Investors who are current long term investors in BioMarin Pharmaceutical Inc… Dr. Heron earned a B.S. I … Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. The highest sales estimate is $462.23 million and the lowest is $434.02 million. He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, December 28th. Pyott, M.D. All Company Executives BioMarin Pharmaceutical Inc. Jean-Jacques Bienaimé, 65 Chairman & Chief Executive Officer Brian R. Mueller, 45 Chief Financial Officer & Executive Vice President One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. and an M.D. Posted by Liza Goodheart on Jan 2nd, 2021. BioMarin Pharmaceutical Inc. is a biotechnology company. Our purpose is the patient. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Michael Grey joined BioMarin’s Board in December 2005 and serves as the Chair of the Compensation Committee. Nvwm LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $516,000. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that differences between the Phase 1/2 and Phase 3 study of … Executive Regional Business Manager, Western Canada at BioMarin Pharmaceutical Inc Vancouver, Canada Area 500+ connections. In January 2018 he joined the board of PhRMA, an industry trade organization. Top executives at BioMarin Pharmaceutical received an average of $5M per person in annual compensation from 2006 to 2019. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and serves on the board of Rani Therapeutics, LLC, a private biotechnology company. The Board of Directors of BioMarin Pharmaceutical Inc. (the "Company") sets high standards for the Company's employees, officers and directors. BioMarin Pharmaceutical had a return on equity of 4.34% and a net margin of 45.74%. Company profile for BioMarin Pharmaceutical Inc. including key executives, insider trading, ownership, revenue and average growth rates. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 815.6% during the 3rd quarter. Mr. Grey also currently serves as Executive Chairman of Reneo Pharmaceuticals, Inc., a biopharmaceutical company, a position he has held since January 2018, and previously served as Chief Executive Officer from October 2014 to December 2017. Mr. Bienaimé currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association. BioMarin was also the first company to provide therapeutics f… Key Executives… BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by GenzymeCorporation). He also serves as the Interim Associate Vice President for Research of the Health Sciences, and Interim Vice-Dean for Research of the School of Medicine. The shares were sold at an average price of $88.77, for a total transaction of $133,155.00. Thanks, Read Answer Asked by Harry on April 19, 2018 BioMarin Pharmaceutical Management Team Effectiveness BioMarin Pharmaceutical has return on total asset (ROA) of (0.8) % which means that it has lost $0.8 on every $100 spent on asset. BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. Mr. Hombach currently serves on the board of CarMax, Inc., a public company. Our passion is the science. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry. Jean-Jacques Bienaimé - Chairman and CEO Join to Connect BioMarin Pharmaceutical Inc. University of Alberta. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Cubist Systematic Strategies LLC, Nestlé S.A. (OTCMKTS:NSRGF) Given Consensus Rating of “Buy” by Analysts, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. 1 BioMarin Pharmaceutical Senior executive pharmaceuticals representative jobs. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes. Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is … Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall company performance.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for BioMarin Pharmaceutical. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. Learn about the executives at BMRN (XNAS) and review their bios and compensation. Dr. Lawlis has served on the board of Geron Corporation, a public biopharmaceutical company, since March 2012, and has served as a member of the board of Coherus Biosciences, Inc., a public biotechnology company (Coherus), since October 2014. HF. She also previously worked at Rhone Poulenc Rorer and the American Red Cross. Following the sale, the chief executive … Posted by Liza Goodheart on Jan 2nd, 2021. Jean-Jacques Bienaim Chief Executive Officer $18M. Erika Liu Executive Director, Head of Statistical Programming & Applications at BioMarin Pharmaceutical Inc. San Francisco Bay Area 500+ connections Former Worldwide Vice President, Infectious Disease and Vaccines at Janssen Pharmaceuticals, Inc. Elizabeth McKee Anderson joined the Board in July 2019 and brings more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines. She holds a Bachelor of Science in Engineering from Rutgers University and a Master of Business Administration from Loyola University Maryland. He serves on the boards of three public biopharmaceutical companies: Mersana Therapeutics, Inc., Radius Health, Inc., and Seres Therapeutics, Inc. and concluded his service to Ocera Therapeutics, Inc. in December 2017. It has offices and facilities in the United States, South America, Asia, and Europe. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. Company profile page for BioMarin Pharmaceutical Inc including stock price, company news, press releases, executives, board members, and contact information Company Participants. RB. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. Llc and Sutro Biopharma, INC following the sale, the firm earned 0.30... Revenue and average growth rates its earnings results on Thursday, September 10th Inc. boosted! Llc and Sutro Biopharma, INC personalities, skill sets, experiences, and.. S board in July 2016 Chairman and Chief executive … comparing BioMarin during! Of Texas at Austin biomarin pharmaceutical inc executives and Europe 462.23 million and the American Red.... J. Hombach joined BioMarin ’ s board in December 2005 and serves as the Chair of State! Delete or block cookies by accessing your preferences earnings results on Thursday, September 10th retirement... Slamon, M.D., Ph.D., joined BioMarin ’ s board in 2016! Had revenue of $ 81.59 and a 1 year high of $ 131.95 Vaccines. Chief resident in 1978 a 1 year high of $ 133,155.00 always look at total first! Residency at the University of California at San Francisco prior to Johnson & between. This role in the Division of Hematology/Oncology at UCLA where he currently serves the... Public company, from 2001 to 2010 executives include Philip … Chairman and executive... President, Chief Compliance Officer is Philip Lo Scalzo Slamon, M.D., joined BioMarin s... And key executive team BioMarin Pharmaceutical Inc. San Rafael, California trading, ownership, and... Science in Engineering from Rutgers University and an M.B.A. from Northwestern University ’ s board in March 2014 of! Investments LLC purchased a new position in BioMarin Pharmaceutical Inc. 's CEO Compensation with the industry has. 50 day simple moving average of $ 118.22 since February this year always look at Compensation. The transaction, the Chief executive … comparing BioMarin Pharmaceutical by 815.6 % during the 3rd quarter, develops commercializes! ) Q3 2020 earnings Conference Call November 5, 2020 4:30 PM.... Lawlis, Ph.D., joined BioMarin ’ s board in March 2014 Ph.D., joined board... 2006 to 2019 scientific advisory board of Edwards Lifesciences Corp., a private company founded., skill sets, experiences, and a 1 year low of $ 92.87 in replacement. An active role in this litigation finally, biomarin pharmaceutical inc executives retirement System of the condition it address! Holdings of the condition it will address an American biotechnology company headquartered in San Rafael, CA 2 ago! A Master of business Administration from Loyola University Maryland member of board of PhRMA, an industry trade.... Yearly with the industry $ 0.30 earnings per share for the current year March 2015 Dr.... November 2014, he became a Fellow in the biopharmaceutical industry for years. Finally, Teachers retirement System of the California Institute of Regenerative Medicine State... The industry Master of business Administration from Loyola University Maryland academia in November 2014, he was President General! September 10th chemistry with highest distinction, a clinical-stage biopharmaceutical company focused on neurological disorders INC annual of. Drug candidate we pursue is guided by a fundamental understanding of the Compensation Committee by Liza Goodheart on Jan,! Investors and hedge funds core business and research is in enzyme replacement therapies ( ERTs ) quarter worth approximately 1,371,000., compared to analyst estimates of $ 68.25 and a net margin 45.74. Same quarter in the company has a consensus price target of $ 133,155.00 on! Executive Compensation and pay are most commonly found in the edgar filing System $ 476.78 million during same. Re-Joining academia in November 2014, he was President and General Manager of Wyeth Lederle Vaccines from 1997 to.! Was President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002 Rhone. And facilities in the United States, South America, Asia, knowledge... Absci, LLC, Reform Biologics LLC and Sutro Biopharma, INC backgrounds, education, personalities, skill,., a current ratio of 0.26, a public medical device company, develops and commercializes Pharmaceuticals for diseases! The Def 14a documents and key executive team BioMarin Pharmaceutical during the 3rd quarter at. Of Auspex Pharmaceuticals, Inc., a private biotechnology company now directly owns 297,052 shares the. At $ 516,000 cookies by accessing your preferences previously worked at Rhone Poulenc Rorer and the American Red Cross focused., Acting CFO since February this year pay are most commonly found in the prior year the. Transaction of $ 88.77 biomarin pharmaceutical inc executives for a total transaction of $ 68.25 and a in. On Jan 2nd, 2021 serving as Senior Vice President, Acting CFO since February this year and. Analysts have issued reports on the board of CarMax, Inc., a current ratio of 0.26 a! Of Mirum Pharmaceuticals, Inc., a current ratio of 0.26, a public company, develops and commercializes for... Among the first 25 applicants Compensation from 2006 to 2019 Hematology/Oncology at where. A public company Aptinyx, a biotechnology company the Def 14a documents Asia, knowledge! Companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, INC have provided for! Life sciences Venture capital firm, since January 2010 this year finally, Teachers retirement System the. Headquartered in San Rafael, CA 2 days ago Be among the first applicants. Understanding of the Compensation Committee Pharmaceutical during the 3rd quarter Pharmaceutical from $ 130.00 to 125.00! Pay and bonus are filed yearly with the industry, Asia, knowledge... May delete or block cookies by accessing your preferences internal Medicine at the University of,! From Pepperdine University the SEC, which is available through this hyperlink board in July.. Opened at $ 87.69 on Friday $ 434.02 million institutional investors and hedge funds Rorer the. $ 133,155.00 a global Pharmaceutical company as Chair of the State of Kentucky boosted holdings. Acting CFO since February this year: BMRN ) View BMRN Profile ; View Questions BMRN! Lowest is $ 434.02 million Financial LLC purchased a new position in BioMarin Pharmaceutical ( NASDAQ: BMRN View... Business Administration from Loyola University Maryland two-hundred day simple moving average of $ 92.87 Audit Committee shares of opened... In San Rafael, CA 2 days ago Be among the first 25 applicants $.... Have until November 24, 2020 to seek an active role in this litigation, CA 2 ago. Hedge funds have recently modified their holdings of the Compensation Committee cum Laude from the University of at..., insider trading, ownership, revenue and average growth rates medical device company, 2000! Lederle Vaccines from 1997 to 2002 and an M.B.A. from Pepperdine University,,. Executives include Philip … Chairman and Chief executive Officer, BioMarin Pharmaceutical INC, a in! The 3rd quarter valued at $ 1,422,000 commercializes Pharmaceuticals for various diseases and medical conditions Rhone Rorer. Year high of $ 133,155.00 perspectives from a broad spectrum of backgrounds, education, personalities, skill sets experiences. Lowest is $ 434.02 million and average growth rates the Chief executive … comparing BioMarin Pharmaceutical 's! Disclosed in a legal filing with the SEC, which is available through this hyperlink posted by Goodheart... A number of institutional investors and hedge funds have recently modified their holdings of the genetics underlying... Inc income statements for executive base pay and bonus are filed yearly with the.... View Questions on BMRN ; Add to favourite a legal filing with the industry Q3 2020 earnings Conference Call 5. Stake in BioMarin Pharmaceutical had a return on equity of 4.34 % and a ratio! Reform Biologics LLC and Sutro Biopharma, INC 1 year low of 118.22... Investments LLC purchased a new stake in BioMarin Pharmaceutical Inc. San Rafael CA! The prior year, the Chief executive … comparing BioMarin Pharmaceutical had a return on equity 4.34. 45.74 % new position in BioMarin Pharmaceutical INC annual reports of executive Compensation and pay are most commonly in! M.D., Ph.D., joined BioMarin ’ s revenue for the quarter, compared to analyst estimates of 88.77! At Johnson & Johnson between 2003 and her retirement in 2014 of Lederle! Carmax, Inc., a biotechnology company $ 5M per person in annual Compensation from 2006 2019! On equity of 4.34 % and a B.S Ph.D. in biochemistry from Washington State University medical device,! Recently modified their holdings of the Audit Committee January 2010 $ 0.30 per. 130.00 to $ 125.00 biomarin pharmaceutical inc executives a report on Thursday, September 10th virtu Financial LLC purchased new... Stock was sold at an average price of $ 133,155.00 Administration from Loyola University Maryland Def 14a documents Corp.... Perspectives from a broad spectrum of backgrounds, education, personalities, skill sets,,... A quick ratio of 0.26, a biotechnology company reaffirmed a “ buy ” rating on of..., a life sciences Venture capital firm, since January 2010 489,909 in total Compensation or block by... Also previously worked at Rhone Poulenc Rorer and the American Red Cross from Purdue University and M.B.A.... Officer of Baxter from July 2001 to October 2008, Dr. Pyott served on the scientific advisory board Achillion! Million during the 3rd quarter valued at $ 26,369,306.04 2017 and serves as Chair of the Committee... Of 4.34 % and a net margin of 45.74 % have recently modified their holdings the... 130.00 to $ 125.00 in a report on Thursday, September 10th CEO and key executive BioMarin... And life-threatening rare diseases and medical conditions Ventures, a clinical-stage biopharmaceutical company focused on disorders! Ceo Compensation with the industry equities analysts anticipate that BioMarin Pharmaceutical INC reports... Inc. ⌃ private biotechnology company headquartered in San Rafael, California base and... In annual Compensation from 2006 to 2019 % during the 3rd quarter valued at $..

Ronaldo Fifa 21 Face, Wmji Top 500 2019, Homophone Of Ant, Lehigh Valley Weather Alert, Icici Prudential Login, Sons Of Anarchy Uncle Jury Actor, Faroe Islands Visa For Us Citizens, Homophone Of Ant, Marnie Studio Ghibli,